Folate receptor α associated with triple-negative breast cancer and poor prognosis

Archives of Pathology and Laboratory Medicine

Volumn 138, Issue 7, 2014, Pages 890-895

  Zhang, Zhang ^a   Wang, Jianmin ^b   Tacha, David E ^c   Li, Pamela ^d   Bremer, Ryan E ^c   Chen, Huijiao ^a   Wei, Bing ^a   Xiao, Xiuli ^e   Da, Jiping ^f   Skinner, Kristin ^d   Hicks, David G ^d   Bu, Hong ^a   Tang, Ping ^d  

^a SICHUAN UNIVERSITY   (China)

^b RTI HEALTH SOLUTIONS   (United States)

^c Biocare Medical   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e SOUTHWEST MEDICAL UNIVERSITY   (China)

^f Japan China Friendship Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; FOLATE RECEPTOR 1; FOLR1 PROTEIN, HUMAN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; CARCINOMA, DUCTAL, BREAST; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FOLATE RECEPTOR 1; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84904020574     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2013-0309-OA     Document Type: Article

References (27)

1. Jhaveri MS, Rait AS, Chung KN, Trepel JB, Chang EH. Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. Mol Cancer Ther. 2004;3(12):1505-1512.
2. Coney LR, Tomassetti A, Carayannopoulos L, et al. Cloning of a tumorassociated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res. 1991;51(22):6125-6132.
3. Garin-Chesa P, Campbell I, Saigo PE, et al. Trophoblast and ovarian cancer antigen LK26: Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol. 1993;142(2):557-567.
4. Hartmann LC, Keeney GL, Lingle WL, et al. Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer. 2007;121(5):938-942.
5. Allard JE, Risinger JI, Morrison C, et al. Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas. Gynecol Oncol. 2007;107(1):52-57.
6. Brown Jones M, Neuper C, Clayton A, et al. Rationale for folate receptor alpha targeted therapy in "high risk" endometrial carcinomas. Int J Cancer. 2008; 123(7):1699-1703.
7. Shia J, Klimstra DS, Nitzkorski JR, et al. Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: Patterns and biological significance. Hum Pathol. 2008;39(4):498-505.
8. O'Shannessy DJ, Yu G, Smale R, et al. Folate receptor alpha expression in lung cancer: Diagnostic and prognostic significance. Oncotarget. 2012;3(4):414-425.
9. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines: Physiologic and clinical implications. Cancer. 1994;73(9):2432-2443.
10. Parker N, Turk MJ, Westrick E, et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem. 2005;338(2):284-293.
11. O'Shannessy DJ, Somers EB, Maltzman J, Smale R, Fu YS. Folate receptor alpha (FRA) expression in breast cancer: Identification of a new molecular subtype and association with triple negative disease. SpringerPlus. 2012;1(1):22-30
12. Tacha D, Bremer R. Folate receptor alpha is frequently expressed in ER/PR negative and triple negative breast cancers. Mod Pathol. 2013;26(suppl 2):71A.
13. Dosio F, Milla P, Cattel L. EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers. Curr Opin Investig Drugs. 2010;11(12):1424-1433.
14. Pribble P, Edelman MJ. EC145: A novel targeted agent for adenocarcinoma of the lung. Expert Opin Investig Drugs. 2012;21(5):755-761.
15. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367-5374.
16. Cheang MCU, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14(5):1368-1376.
17. Bhargava R, Beriwal S, Dabbs DJ, et al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: A single institutional experience with 359 cases. Cancer. 2010; 116(6):1431-1439.
18. Yanagawa M, Ikemot K, Kawauchi S, et al. Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumor with different genotype. BMC Res Notes. 2012;5:376. doi:10:1186/1756-0500-5-376.
19. Quinn AM, Tang P, Yang Q, Bourne PA. Tissue array construction: Pitfalls, problems and progress. Appl Immunohistochem Mol Morophol. 2008;16(3):287-290.
20. Lin Y, Hatem J, Wang J, et al. Tissue microarray-based immunohistochemical study can significantly underestimate the expression of HER2 and progesterone receptor in ductal carcinoma in situ of the breast. Biotech Histochem. 2011;86(5):345-350.
21. Kelley KM, Rowan BG, Ratnam M. Modulation of the folate receptor alpha gene by the estrogen receptor: Mechanism and implications in tumor targeting. Cancer Res. 2003;63(11):2820-2828.
22. Kalli KR, Oberg AL, Keeney GL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008;108(3):619-626.
23. Miotti S, Bagnoli M, Tomassetti A, et al. Interaction of folate receptor with signaling moleculas lyn and Gai-3 in detergent-resistant complexes from the ovary carcinoma cell line IGROV1. J Cell Sci. 2000;113(pt 2):349-357.
24. Ebel W, Routhier EL, Foley B, et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun. 2007;7:6.
25. Konner JA, Bell-McGuinn KM, Sabbatini P, et al. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: A phase I study. Clin Cancer Res. 2010;16(21):5288-5295.
26. Farrell C, Schweizer C, Wustner J, et al. Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer. Cancer Chemother Pharmacol. 2012;70(5):727-734.
27. Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: Implications in targeted therapy. Adv Drug Deliv Rev. 2004;56(8):1067-1084.